Compare Garrett Motion Inc. Common Stock (GTX) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garrett Motion Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Garrett Motion Inc. Common Stock trades at $25.32 (market cap $4.81B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Garrett Motion Inc. Common Stock is the larger of the two by market cap, and Garrett Motion Inc. Common Stock pays the higher dividend (1.24%). Which is the better fit depends on your goals — on Pluang, investors hold Garrett Motion Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| GTX | OGN | |
|---|---|---|
Market Cap | $4.81B | $3.62B |
Volume | 2,684,088 | 2,892,999 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.23 | $13.81 |
52-Week Low | $12.50 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $6.06B | $11.04B |
Dividend Yield | 1.24% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garrett Motion (GTX) trades at $25.78, showing minimal daily movement with a 0.08% gain. The stock exhibits bearish technical signals despite strong fundamental performance, including three consecutive quarterly earnings beats and improving profit margins. Recent news highlights the company's leadership in turbocharging and electrification technologies, with Q3 2026 results expected on October 29th. Institutional activity shows significant positions from BlackRock and Deutsche Bank, while analyst consensus remains positive with a $38 price target representing 47% upside potential.
GTX presents a compelling value opportunity with attractive valuation multiples (P/E 14.16, P/S 1.35) and consistent earnings outperformance. However, technical weakness and competitive pressures in automotive technology create near-term headwinds. The upcoming Q3 earnings report on October 29th will be crucial for validating the company's raised 2026 outlook and momentum trajectory.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garrett Motion Inc. Common Stock
Garrett Motion develops turbocharging and air-boosting technologies for vehicles. Its products are used in internal combustion, hybrid, and other vehicle powertrains.
Read more on GTX →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
